Uniqure NV: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Uniqure NV Unternehmen

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Uniqure NV Informationen



BörsenkürzelQURE

Name des UnternehmensUniqure NV

IPO-datumFeb 05, 2014

CEOMr. Matthew (Matt) Kapusta, CPA

Anzahl der mitarbeiter209

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 05

AddressePaasheuvelweg 25a

StadtAMSTERDAM

BörseNASDAQ Global Select Consolidated

LandNetherlands

Postleitzahl1105 BP

Telefon31202406000

Websitehttps://www.uniqure.com/

BörsenkürzelQURE

IPO-datumFeb 05, 2014

CEOMr. Matthew (Matt) Kapusta, CPA

Führungskräfte von Uniqure NV



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Christian Klemt, CPA

Chief Financial Officer

99.26K

--

Walid Abi-Saab

Chief Medical Officer

34.63K

-4.06%

Dr. Robert Gut, M.D., Ph.D.

Non-Executive Director

32.06K

-32.72%

Mr. Madhavan (Madhu) Balachandran

Non-Executive Independent Director

29.62K

+24.66%

Dr. Jeremy P. Springhorn, Ph.D.

Non-Executive Independent Director

29.61K

+24.66%

Dr. Leonard E. Post, Ph.D.

Non-Executive Independent Director

21.86K

+36.61%

Ms. Rachelle Suzanne Jacques

Non-Executive Independent Director

20.27K

+40.66%

Dr. Jeannette Potts, J.D., Ph.D.

Chief Legal and Compliance Officer and Corporate Secretary

15.67K

-22.96%

Mr. Jack L. Kaye, CPA

Non-Executive Independent Director

--

Mr. David Meek

Non-Executive Independent Chairman of the Board

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Christian Klemt, CPA

Chief Financial Officer

99.26K

--

Walid Abi-Saab

Chief Medical Officer

34.63K

-4.06%

Dr. Robert Gut, M.D., Ph.D.

Non-Executive Director

32.06K

-32.72%

Mr. Madhavan (Madhu) Balachandran

Non-Executive Independent Director

29.62K

+24.66%

Dr. Jeremy P. Springhorn, Ph.D.

Non-Executive Independent Director

29.61K

+24.66%

Dr. Leonard E. Post, Ph.D.

Non-Executive Independent Director

21.86K

+36.61%

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sat, Nov 8

Aktionäre

Aktionärstypen

Aktionäre

Anteil

RTW Investments L.P.

8.28%

EcoR1 Capital, LLC

6.40%

Vestal Point Capital, LP

5.94%

Avoro Capital Advisors LLC

5.82%

abrdn Inc.

4.72%

Andere

68.84%

Aktionäre

Anteil

RTW Investments L.P.

8.28%

EcoR1 Capital, LLC

6.40%

Vestal Point Capital, LP

5.94%

Avoro Capital Advisors LLC

5.82%

abrdn Inc.

4.72%

Andere

68.84%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor/Hedge Fund

45.59%

Hedge Fund

18.44%

Investment Advisor

14.82%

Research Firm

6.51%

Corporation

3.88%

Venture Capital

3.21%

Individual Investor

1.50%

Private Equity

0.98%

Bank and Trust

0.24%

Andere

4.83%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

368

55.15M

89.53%

-7.50M

2025Q2

396

55.26M

101.06%

-1.58M

2025Q1

429

55.29M

101.00%

-4.83M

2024Q4

431

46.57M

86.23%

-10.92M

2024Q3

431

43.93M

89.29%

-10.96M

2024Q2

435

37.07M

76.08%

-15.19M

2024Q1

449

38.56M

80.27%

-17.69M

2023Q4

454

43.54M

90.77%

-8.61M

2023Q3

462

41.52M

86.64%

-16.34M

2023Q2

452

41.43M

87.10%

-18.53M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

RTW Investments L.P.

5.16M

8.37%

+892.80K

+20.93%

Jun 30, 2025

EcoR1 Capital, LLC

3.99M

6.48%

--

Jun 30, 2025

Vestal Point Capital, LP

3.70M

6.01%

-1.09M

-22.80%

Jun 30, 2025

Avoro Capital Advisors LLC

3.63M

5.88%

+1.45M

+66.67%

Jun 30, 2025

abrdn Inc.

2.75M

4.47%

+535.16K

+24.15%

Jun 30, 2025

Bristol Myers Squibb

2.39M

3.88%

--

Sep 30, 2024

Jefferies LLC

2.10M

3.4%

+2.10M

--

Jun 30, 2025

Nantahala Capital Management, LLC

2.05M

3.33%

-704.11K

-25.55%

Jun 30, 2025

Franklin Advisers, Inc.

1.61M

2.61%

-382.31K

-19.23%

Jun 30, 2025

Two Sigma Investments, LP

1.60M

2.6%

+15.67K

+0.99%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

WisdomTree BioRevolution Fund

4.09%

Global X Genomics & Biotechnology ETF

3.36%

Virtus LifeSci Biotech Clinical Trials ETF

2.63%

Invesco NASDAQ Future Gen 200 ETF

1.73%

SPDR S&P Biotech ETF

1.24%

Alger Mid Cap 40 ETF

1.07%

Tema Heart & Health ETF

0.73%

Direxion Daily S&P Biotech Bull 3X Shares

0.65%

Harbor Health Care ETF

0.6%

Invesco Nasdaq Biotechnology ETF

0.34%

WisdomTree BioRevolution Fund

Anteil4.09%

Global X Genomics & Biotechnology ETF

Anteil3.36%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil2.63%

Invesco NASDAQ Future Gen 200 ETF

Anteil1.73%

SPDR S&P Biotech ETF

Anteil1.24%

Alger Mid Cap 40 ETF

Anteil1.07%

Tema Heart & Health ETF

Anteil0.73%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.65%

Harbor Health Care ETF

Anteil0.6%

Invesco Nasdaq Biotechnology ETF

Anteil0.34%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten